Metastatic Urothelial Cancer Active Not Recruiting Phase 2 Trials for Enfortumab vedotin (DB13007)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0066157 (Metastatic Urothelial Cancer) | Active Not Recruiting | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT04995419 | A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy | Treatment |